Williams Cancer Institute

CEO on an AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC

Syncromune founder Jason R Williams, MD Work is the Basis of This Study.

Reference: Ali Gorman, Brad Loncar, & Brian Orelli. (2024, April 9). Syncromune’s AACR late-breaker of phase 1 data for the sync-T immunotherapy drug-device combo in mCRPC. BiotechTV. https://www.biotechtv.com/post/syncromune-april-8-2024

Related Posts

Blog 21 de mayo de 2024
Blog 20 de mayo de 2024
Blog 06 de mayo de 2024
1 2 3 111